SAMHSA released a formal 2026 advisory telling primary care physicians to stop treating every cannabis user as a disorder patient. It urges doctors to distinguish between medical marijuana use and diagnosable cannabis use disorder. This is not a minor clarification. For millions of patients, it is a long-overdue federal validation of what cannabis medicine physicians have argued for years.
Table of Contents
- Medical Marijuana vs. Cannabis Use Disorder: What SAMHSA’s 2026 Advisory Means for Patients and Physicians
Medical Marijuana vs. Cannabis Use Disorder: What SAMHSA’s 2026 Advisory Means for Patients and Physicians
The federal government’s own substance abuse agency is now telling doctors that using cannabis as a medicine is not the same thing as having a cannabis problem. Here is why that distinction matters clinically, why it has taken this long, and what both patients and physicians need to understand going forward.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →A federal health agency formally acknowledging the clinical distinction between therapeutic cannabis use and cannabis use disorder is directly relevant to every patient in our practice. This guidance validates a framework we apply daily with our patient population and has clear implications for how physicians across all specialties should document, discuss, and refer cannabis-using patients.
- What SAMHSA’s new 2026 advisory actually says about medical marijuana and cannabis use disorder
- Why the distinction between therapeutic use and diagnosable disorder matters for patient care, insurance, and employment
- What clinical signals physicians are being told to look for before applying a CUD diagnosis
- Where current diagnostic frameworks still fall short, and what patients should know to protect themselves
- Dr. Caplan’s clinical perspective after 20 years and more than 30,000 patient interactions in Massachusetts
- SAMHSA’s May 2026 advisory formally tells doctors that medical marijuana use and cannabis use disorder are not the same thing, and should not be treated as such.
- The advisory instructs clinicians to evaluate cannabis use based on clinical signs of harm, not simply because a patient uses cannabis.
- Cannabis is the third most used psychoactive substance in the U.S. An estimated 44.3 million Americans used it in 2024, while approximately 20.6 million met criteria for cannabis use disorder.
- This guidance is significant for patients who fear stigma or misdiagnosis, and for physicians who need a clearer framework to support patients using cannabis therapeutically.
For years, one of the most persistent harms in the medical cannabis space has not been a pharmacological one. It has been a diagnostic one. Patients seeking care for chronic pain, sleep disorders, anxiety, or cancer-related symptoms have been told by well-meaning physicians that their cannabis use is a problem in itself, not a tool they are using to address a problem. The stigma of that framing has kept countless people from honest conversations with their doctors, from accessing appropriate care, and from feeling safe in their own medical relationships.
SAMHSA’s advisory does not resolve this entirely. But it formally establishes, at the federal level, that using cannabis is not automatically a disorder. That matters for clinical practice, for insurance documentation, and for the broader culture of medical cannabis care in the United States.
The Substance Abuse and Mental Health Services Administration released its advisory titled Addressing Cannabis Use Disorder in Primary Care Settings: A Lifespan Approach in May 2026. The document is addressed to primary care physicians, pediatricians, adolescent medicine specialists, and geriatricians. Its central clinical argument is that cannabis use disorder (CUD) requires a positive finding of clinically significant impairment or distress, not simply evidence that a patient uses cannabis. SAMHSA instructs clinicians to look at frequency, product type, THC content, therapeutic intent, medical authorization status, and the presence of symptoms such as withdrawal, cravings, failed attempts to reduce use, and functional interference with work, school, or family life before assigning a CUD diagnosis.
The advisory also acknowledges that some patients describe their use as medical even when it lacks formal authorization or clear therapeutic purpose, and it encourages clinicians to investigate that context critically rather than accepting or dismissing the label automatically. The document covers cannabis use across five life stages: adolescence, young adulthood, middle adulthood, older adulthood, and pregnancy. It references SAMHSA’s own data showing 44.3 million Americans aged 12 and older reported past-month cannabis use in 2024, a number that has risen consistently since 2021, alongside an estimated 20.6 million people meeting diagnostic criteria for cannabis use disorder in the same year.
The Diagnostic Problem SAMHSA Is Trying to Solve
Cannabis use disorder, as defined by the DSM-5, requires at least two of eleven criteria to be present within a 12-month period. Those criteria include things like tolerance, withdrawal, use in larger amounts than intended, failed efforts to cut back, significant time spent obtaining or using cannabis, and continued use despite persistent social or health problems it is causing. The diagnosis ranges from mild (two or three criteria) to severe (six or more).
The problem is that several of these criteria can be present in patients who are using cannabis entirely appropriately under a physician’s care. Tolerance, for example, is a normal pharmacological adaptation. A patient using medical cannabis for chronic pain will often require adjusted doses over time. That is not a disorder. It is physiology. Similarly, a patient who plans their day around medication timing, who spends time obtaining a product through a licensed dispensary, or who would experience sleep disruption if they suddenly stopped using cannabis may technically meet multiple DSM-5 criteria without having anything resembling a behavioral health problem.
This is a known limitation of the DSM-5 framework for cannabis. SAMHSA’s advisory does not fix that limitation directly. What it does is tell practicing physicians that context matters and that the diagnostic threshold must account for why the patient is using cannabis, under whose supervision, and whether it is actually causing harm.
Why This Guidance Arrives Now
The timing is not accidental. The federal landscape around cannabis has shifted meaningfully in 2026. The Department of Justice finalized an order placing FDA-approved cannabis products and state-licensed medical marijuana products into Schedule III of the Controlled Substances Act, with an administrative hearing on broader cannabis rescheduling scheduled for June 29. States have moved aggressively to expand programs: 41 states now have operational medical marijuana programs. The TSA updated its travel guidance this week to reflect that medical cannabis is an allowable item in both carry-on and checked bags, subject to applicable laws at the destination.
In Massachusetts, where CED Clinic serves patients across the state, the Cannabis Control Commission has been an active regulator, and state regulators announced this week that they will begin auditing THC potency labels on cannabis products. These developments collectively signal that the federal posture toward cannabis is evolving, and SAMHSA’s advisory reflects an acknowledgment that primary care medicine needs updated frameworks to manage the patient population that is actually sitting in front of doctors every day.
What Clinicians Are Actually Being Told
SAMHSA’s guidance is practical. It asks clinicians to gather specific information before drawing diagnostic conclusions about a cannabis-using patient. That includes product type (flower, oil, capsule, topical), THC and CBD content, frequency and pattern of use, method of administration, and whether use is tied to a medical certification or therapeutic intent. It asks whether the patient has experienced what they interpret as withdrawal symptoms, whether they have tried to reduce use and failed, and whether cannabis use is interfering with their function in daily life.
That is, in essence, a cannabis intake history. It is the kind of assessment that cannabis medicine specialists conduct at every appointment. What is notable is that it is now being codified as standard of care guidance for primary care, where most patients who use cannabis will be seen, and where many have historically encountered either dismissal or misdiagnosis when the topic comes up.
SAMHSA also highlights differences between THC and CBD in terms of risk profiles, notes the potential for cannabis-induced psychosis in vulnerable individuals, and recommends evidence-based treatment for patients who do meet CUD criteria. It does not minimize the reality that cannabis use disorder is a genuine clinical condition that affects a meaningful portion of the population. The advisory is calibrated, not dismissive of risk.
SAMHSA’s advisory is a policy document, not a clinical trial. It does not present new outcome data. It does not establish validated screening instruments for distinguishing therapeutic use from CUD. And it does not update or formally challenge the DSM-5 criteria themselves, which continue to apply tolerance and withdrawal as diagnostic indicators regardless of clinical context.
The advisory also does not address how EHR systems, insurance coding, or prescribing databases should handle patients who use cannabis medically. A physician following SAMHSA’s guidance in good faith may still face structural pressure from billing systems and quality metrics that treat cannabis use as a risk flag, regardless of clinical intent.
How This Fits the Broader Clinical Conversation
The research literature has long suggested that medical cannabis patients and recreational users present with meaningfully different risk profiles. Patients using cannabis under a physician’s guidance for documented conditions tend to use lower doses with greater intention, have a clear target symptom they are tracking, and are embedded in a care relationship that provides oversight and adjustment. That clinical context is predictive of outcomes in a way that the DSM-5 criteria, used bluntly, cannot capture.
SAMHSA’s advisory represents an institutional convergence with what the clinical cannabis medicine community has been documenting for years. It arrives against a backdrop of two significant legislative shifts: cannabis rescheduling and an expanding body of Phase 3 trial data showing efficacy in pain, sleep, and neurological conditions. Federal health agencies are being forced to reconcile their guidance with the clinical reality that cannabis is medicine for a very large number of Americans, and that those patients deserve accurate, nuanced evaluation rather than reflexive stigmatization.
Every week in my clinic, I see patients who have been carrying a quiet shame. Not because they have a substance problem, but because a prior physician, sometimes well-intentioned, sometimes rushed, flagged their cannabis use in a way that felt like a verdict. They come in defensive. They expect judgment. That dynamic costs us time and trust, and it gets in the way of good care. So when I read SAMHSA’s advisory, what I felt first was relief. Not surprise. Relief that the federal infrastructure is catching up to what clinical practice has required for a long time.
The number that has always struck me is this: we have roughly 44 million Americans using cannabis in a given month, and roughly 20 million of them are estimated to meet criteria for cannabis use disorder. That second number is not small. CUD is real. It affects people’s lives. But it means that about half of all active cannabis users are using cannabis without a disorder, and a significant portion of them are using it for medical reasons with a physician’s knowledge. Treating all of them as a single clinical category has never made sense.
What I want to push back on gently, even in welcoming this advisory, is the continued reliance on DSM-5 criteria that were not designed with the medical cannabis patient in mind. Tolerance is a classic example. I have patients on stable doses of cannabis oil for neuropathic pain who have adjusted their dose once in three years. I have other patients who have gradually titrated upward while managing a degenerative condition. In both cases, their tolerance profile is a marker of clinical management, not behavioral dysregulation. But the DSM-5 criterion does not make that distinction. A primary care physician following the criteria by the book, without the context that SAMHSA is now asking them to seek, would flag both patients as meeting at least one indicator of CUD.
The practical implication for my patients in Massachusetts, and for patients anywhere with a medical authorization, is this: document your use. Keep your certification current. Know your dosing and the conditions you are managing. When you see any physician, not just a cannabis specialist, come prepared to explain your cannabis use the way you would explain any other medication. Tell them the condition, the dose, the product, and the outcomes you are tracking. That kind of clinical presentation changes the conversation.
The deeper issue here is systemic. We do not have enough physicians trained in cannabis medicine to serve the patient population that needs this kind of nuanced evaluation. Most primary care practices are not set up to do a thorough cannabis intake history in a 15-minute appointment. SAMHSA is telling those physicians what to look for. The infrastructure question, how to actually make that happen at scale, is the next conversation the system needs to have. And it is one we are actively working on through CED Clinic and EO Care, because the patients are already here, already using cannabis, and already deserving of the care they came for.
Cannabis Use Disorder
A nuanced topic often reduced to headlines and oversimplified narratives. These physician-guided resources explore dependence, addiction risk, policy framing, diagnostic complexity, and what current evidence actually shows.
Is Weed Addictive?
A practical overview of cannabis dependence, habit formation, withdrawal symptoms, and how risk differs across individuals and usage patterns.
Read Article →Understanding Cannabis Use Disorder
A deeper discussion of addiction terminology, diagnostic interpretation, public policy concerns, and why context matters in clinical conversations.
Explore Discussion →Cannabis Dependence: Myths vs Facts
Separates cultural assumptions from clinical evidence, including what research supports, what remains uncertain, and where misconceptions persist.
Review Evidence →Cannabis Use Disorder and Health Outcomes
Examines how cannabis use disorder compares with other substance use disorders in population-level outcome research and public health interpretation.
View Analysis →
Cannabis Use Disorder Deserves Nuance
Public conversations around Cannabis Use Disorder are often shaped by oversimplified headlines, inconsistent definitions, and a lack of clinical context. The reality is more complicated, particularly when discussing therapeutic use, individualized physiology, chronic illness, dependence, withdrawal, and comparative substance risk.
For a physician-guided breakdown of the terminology, research limitations, public health framing, and where current evidence is frequently misunderstood or overstated, explore Dr. Caplan’s detailed analysis below.
Read the Full Explanation →
What a Careful Reader Should Take Away
SAMHSA has not rewritten cannabis medicine. It has updated federal guidance to reflect a clinical reality that has been present in practice for years. The advisory acknowledges that millions of Americans use cannabis for medical reasons, that those patients are not categorically different from other patients managing chronic conditions with a scheduled medication, and that physicians need better tools and frameworks for evaluating cannabis use than the blunt instruments that have historically been applied.
For patients, the takeaway is straightforward: if you use cannabis medically, you have the right to a thorough, non-judgmental evaluation. If a physician categorizes your use as a disorder without asking about your therapeutic intent, dosing, and functional outcomes, that assessment is incomplete. You can ask for a more thorough evaluation. You can seek a second opinion from a physician with cannabis medicine training.
For physicians, the guidance is an invitation to update a clinical workflow that has not kept pace with the patient population. Asking about cannabis the way you ask about any other medication, with attention to indication, dose, duration, and outcomes, is now federal guidance. The clinical culture needs to follow.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Substance Abuse and Mental Health Services Administration. Addressing Cannabis Use Disorder in Primary Care Settings: A Lifespan Approach. Advisory PEP26-07-003. Rockville, MD: SAMHSA, May 2026. Available at: https://library.samhsa.gov/product/advisory-cannabis-use-disorder-primary-care-settings-lifespan/pep26-07-003
Frequently Asked Questions
What is the difference between medical marijuana use and cannabis use disorder?
Medical marijuana use refers to intentional, therapeutic use of cannabis for a documented medical condition, typically under a physician’s supervision and with a valid state authorization. Cannabis use disorder (CUD) is a clinical diagnosis defined by the DSM-5, requiring at least two of eleven criteria related to loss of control over use, functional impairment, and continued use despite harm. The key distinction is whether cannabis use is causing clinically significant problems in the patient’s life, not simply whether they use cannabis.
What does SAMHSA’s 2026 advisory actually say about medical marijuana patients?
SAMHSA’s May 2026 advisory, titled “Addressing Cannabis Use Disorder in Primary Care Settings: A Lifespan Approach,” instructs physicians to evaluate cannabis use based on clinical signs of harm rather than treating every cannabis-using patient as having a disorder. It asks clinicians to gather information about frequency, product type, THC content, therapeutic intent, medical authorization status, and functional outcomes before concluding that a patient meets criteria for CUD.
Can a patient have a valid medical marijuana authorization and also have cannabis use disorder?
Yes, it is possible for a patient to have a medical marijuana authorization and also meet DSM-5 criteria for CUD. Having a therapeutic purpose does not automatically exclude a patient from a CUD diagnosis if their use has escalated beyond therapeutic intent, is causing functional harm, or involves loss of control. The authorization is context, not a diagnostic exemption. SAMHSA’s advisory specifically asks physicians to evaluate both dimensions: the therapeutic intent and the presence of clinical harm markers.
Why is the tolerance criterion in DSM-5 problematic for medical cannabis patients?
Tolerance, one of the eleven DSM-5 CUD criteria, refers to needing more of a substance to achieve the same effect, or experiencing diminished effect with the same amount. In a medical context, tolerance is a normal and expected pharmacological adaptation, particularly in patients managing chronic conditions. A patient who has gradually increased their cannabis dose under physician supervision to maintain symptom control is experiencing therapeutic tolerance, not a behavioral disorder. However, the DSM-5 criterion does not distinguish between these scenarios, which is one of the known limitations of the current diagnostic framework.
How should patients protect themselves from being incorrectly diagnosed with cannabis use disorder?
Patients who use cannabis medically should maintain current documentation of their state authorization and the medical condition being treated. When visiting any healthcare provider, presenting cannabis use the way you would present any other medication, with the condition, dose, product type, and symptom outcomes you are tracking, significantly changes the clinical conversation. If a physician assigns a CUD diagnosis without conducting a thorough evaluation of your therapeutic context, you have the right to request a more complete assessment or to seek a second opinion from a physician with cannabis medicine training.
How many Americans have cannabis use disorder?
According to SAMHSA’s own 2024 data, approximately 20.6 million Americans aged 12 and older met diagnostic criteria for cannabis use disorder. This is out of 44.3 million Americans who reported past-month cannabis use in the same year. Cannabis use disorder is a real clinical condition that affects a significant portion of users, particularly those who begin use in adolescence, use high-potency products frequently, or have co-occurring psychiatric conditions.
What clinical signals should a physician look for before diagnosing cannabis use disorder?
SAMHSA’s advisory instructs clinicians to gather information on frequency and pattern of use, product type and THC content, method of administration, therapeutic intent and medical authorization status, and functional indicators such as withdrawal symptoms, cravings, failed attempts to reduce use, and interference with work, school, family, or health. A minimum of two DSM-5 criteria must be present within a 12-month period for a mild CUD diagnosis. Evaluating context, not just the presence of use, is central to an accurate assessment.
Does SAMHSA’s advisory apply only in states with medical marijuana programs?
SAMHSA’s advisory is a federal guidance document that applies to primary care physicians nationally. However, the distinction between authorized medical use and CUD is most clinically actionable in the 41 states with active medical marijuana programs, where patients may present with valid state certifications. In states without medical programs, physicians still need to evaluate cannabis use contextually, as patients may be using cannabis obtained through legal recreational markets or from neighboring states with medical or recreational access.
How does cannabis rescheduling affect the medical marijuana versus cannabis use disorder discussion?
The Department of Justice’s April 2026 final order moving FDA-approved and state-licensed cannabis products to Schedule III of the Controlled Substances Act changes the legal and research landscape significantly. Schedule III status enables more rigorous clinical trials, improves insurance reimbursement pathways, and reduces the regulatory barriers that have historically limited physician training in cannabis medicine. As the evidence base for medical cannabis grows and federal scheduling more accurately reflects its therapeutic use, the clinical and regulatory frameworks for distinguishing therapeutic use from disorder are likely to become more precise.
Where can patients in Massachusetts get an evaluation from a physician trained in cannabis medicine?
CED Clinic, based in Massachusetts, is a physician-led practice with over 20 years of cannabis medicine experience and more than 30,000 patients served. Dr. Benjamin Caplan and the CED Clinic team conduct comprehensive cannabis evaluations that assess therapeutic use in clinical context, including an assessment of conditions being managed, dosing, product type, and functional outcomes. Patients throughout Massachusetts and beyond can access evaluations in person or through EO Care, a HIPAA-compliant digital health platform offering scalable, affordable, data-informed cannabis care. Visit cedclinic.com or eo.care to learn more.